;PMID: 11048673
;source_file_916.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..65] = [t:0..65]
;1)sentence:[e:71..197] = [t:71..197]
;2)section:[e:201..216] = [t:201..216]
;3)section:[e:220..283] = [t:220..283]
;4)sentence:[e:287..442] = [t:287..442]
;5)sentence:[e:443..636] = [t:443..636]
;6)sentence:[e:637..826] = [t:637..826]
;7)sentence:[e:827..1007] = [t:827..1007]
;8)sentence:[e:1008..1109] = [t:1008..1109]
;9)sentence:[e:1110..1132] = [t:1110..1132]
;10)sentence:[e:1133..1190] = [t:1133..1190]
;11)sentence:[e:1191..1334] = [t:1191..1334]
;12)sentence:[e:1335..1478] = [t:1335..1478]
;13)sentence:[e:1479..1692] = [t:1479..1692]
;14)sentence:[e:1693..1863] = [t:1693..1863]
;15)sentence:[e:1864..1979] = [t:1864..1979]
;16)sentence:[e:1980..2237] = [t:1980..2237]
;17)section:[e:2241..2286] = [t:2241..2286]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1125..1131] microM
;ERROR_Token in entity file but not tree[1131..1132] .
;ERROR_Token in tree file but not entity[1125..1132] microM.

;section 0 Span:0..65
;Comp Biochem Physiol C Toxicol Pharmacol. 2000 Jul;126(3):235-44.
(SEC
  (FRAG (NNP:[0..4] Comp) (NNP:[5..12] Biochem) (NNP:[13..20] Physiol)
        (NNP:[21..22] C) (NNP:[23..30] Toxicol) (NNP:[31..40] Pharmacol)
        (.:[40..41] .) (CD:[42..46] 2000) (CC:[47..55] Jul;126-LRB-)
        (CD:[55..56] 3) (-RRB-:[56..57] -RRB-) (CD:[57..61] :235)
        (HYPH:[61..62] -) (CD:[62..64] 44) (.:[64..65] .)))

;sentence 1 Span:71..197
;Further immunochemical and biocatalytic characterization of CYP1A1 from feral
; leaping mullet liver (Liza saliens) microsomes.
;[131..137]:cyp450:"CYP1A1"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP-2 (JJR:[71..78] Further))
        (JJ:[79..93] immunochemical)
        (NML-1 (-NONE-:[93..93] *P*)))
      (CC:[94..97] and)
      (NP
        (ADJP-2 (-NONE-:[97..97] *P*))
        (JJ:[98..110] biocatalytic)
        (NML-1 (NN:[111..127] characterization))))
    (PP (IN:[128..130] of)
      (NP
        (NP (NN:[131..137] CYP1A1))
        (PP (IN:[138..142] from)
          (NP
            (NML
              (NML (JJ:[143..148] feral)
                (NML (VBG:[150..157] leaping) (NN:[158..164] mullet))
                (NN:[165..170] liver))
              (NML (-LRB-:[171..172] -LRB-) (NNP:[172..176] Liza)
                   (NNP:[177..184] saliens) (-RRB-:[184..185] -RRB-)))
            (NNS:[186..196] microsomes)))))
    (.:[196..197] .)))

;section 2 Span:201..216
;Sen A, Arinc E.
(SEC
  (FRAG (NNP:[201..204] Sen) (NNP:[205..206] A) (,:[206..207] ,)
        (NNP:[208..213] Arinc) (NNP:[214..216] E.)))

;section 3 Span:220..283
;Department of Chemistry, Pamukkale University, Denizli, Turkey.
(SEC
  (FRAG (NNP:[220..230] Department) (IN:[231..233] of)
        (NNP:[234..243] Chemistry) (,:[243..244] ,) (NNP:[245..254] Pamukkale)
        (NNP:[255..265] University) (,:[265..266] ,) (NNP:[267..274] Denizli)
        (,:[274..275] ,) (NNP:[276..282] Turkey) (.:[282..283] .)))

;sentence 4 Span:287..442
;CYP1A is known to play important roles in the metabolism, detoxification and 
;bioactivation of carcinogens and other xenobiotics in animals including
;fish.
;[287..292]:cyp450:"CYP1A"
;[382..393]:substance:"carcinogens"
;[404..415]:substance:"xenobiotics"
(SENT
  (S
    (NP-SBJ-1 (NN:[287..292] CYP1A))
    (VP (VBZ:[293..295] is)
      (VP (VBN:[296..301] known)
        (S
          (NP-SBJ-1 (-NONE-:[301..301] *))
          (VP (TO:[302..304] to)
            (VP (VB:[305..309] play)
              (NP (JJ:[310..319] important) (NNS:[320..325] roles))
              (PP (IN:[326..328] in)
                (NP
                  (NP (DT:[329..332] the) (NN:[333..343] metabolism)
                      (,:[343..344] ,) (NN:[345..359] detoxification)
                      (CC:[360..363] and) (NN:[365..378] bioactivation))
                  (PP (IN:[379..381] of)
                    (NP
                      (NP (NNS:[382..393] carcinogens))
                      (CC:[394..397] and)
                      (NP (JJ:[398..403] other) (NNS:[404..415] xenobiotics))))))
              (PP-LOC (IN:[416..418] in)
                (NP
                  (NP (NNS:[419..426] animals))
                  (PP (VBG:[427..436] including)
                    (NP (NNS:[437..441] fish))))))))))
    (.:[441..442] .)))

;sentence 5 Span:443..636
;In  our laboratory, CYP1A1 was obtained in a highly purified form with a
;specific  content of 15-17 nmol P450 per mg protein from liver microsomes of
;feral fish,  leaping mullet (Liza saliens).
;[463..469]:cyp450:"CYP1A1"
;[537..542]:quantitative-value:"15-17"
;[543..567]:quantitative-units:"nmol P450 per mg protein"
(SENT
  (S
    (PP-LOC (IN:[443..445] In)
      (NP (PRP$:[447..450] our) (NN:[451..461] laboratory)))
    (,:[461..462] ,)
    (NP-SBJ-1 (NN:[463..469] CYP1A1))
    (VP (VBD:[470..473] was)
      (VP (VBN:[474..482] obtained)
        (NP-1 (-NONE-:[482..482] *))
        (PP (IN:[483..485] in)
          (NP (DT:[486..487] a)
            (ADJP (RB:[488..494] highly) (VBN:[495..503] purified))
            (NN:[504..508] form)))
        (PP (IN:[509..513] with)
          (NP
            (NP (DT:[514..515] a) (JJ:[516..524] specific)
                (NN:[526..533] content))
            (PP (IN:[534..536] of)
              (NP
                (NP
                  (NML
                    (QP (CD:[537..539] 15) (HYPH:[539..540] -)
                        (CD:[540..542] 17))
                    (NN:[543..547] nmol))
                  (NP (NN:[548..552] P450)))
                (PP (IN:[553..556] per)
                  (NP (NN:[557..559] mg) (NN:[560..567] protein)))))))
        (PP (IN:[568..572] from)
          (NP
            (NP (NN:[573..578] liver) (NNS:[579..589] microsomes))
            (PP (IN:[590..592] of)
              (NP
                (NP (JJ:[593..598] feral) (NNS:[599..603] fish))
                (,:[603..604] ,)
                (NP
                  (NP (VBG:[606..613] leaping) (NN:[614..620] mullet))
                  (NP (-LRB-:[621..622] -LRB-) (NNP:[622..626] Liza)
                      (NNP:[627..634] saliens) (-RRB-:[634..635] -RRB-)))))))))
    (.:[635..636] .)))

;sentence 6 Span:637..826
;Purified mullet CYP1A1 showed a very high  substrate specificities for
;7-ethoxyresorufin and 7-methoxyresorufin in a  reconstituted system
;containing purified fish P450 reductase and lipid.
;[653..659]:cyp450:"CYP1A1"
;[680..689]:substance:"substrate"
;[708..725]:substance:"7-ethoxyresorufin"
;[730..748]:substance:"7-methoxyresorufin"
;[801..815]:substance:"P450 reductase"
(SENT
  (S
    (NP-SBJ (VBN:[637..645] Purified) (NN:[646..652] mullet)
            (NN:[653..659] CYP1A1))
    (VP (VBD:[660..666] showed)
      (NP
        (NP (DT:[667..668] a)
          (ADJP (RB:[669..673] very) (JJ:[674..678] high))
          (NN:[680..689] substrate) (NNS:[690..703] specificities))
        (PP (IN:[704..707] for)
          (NP (NN:[708..725] 7-ethoxyresorufin) (CC:[726..729] and)
              (NN:[730..748] 7-methoxyresorufin))))
      (PP-LOC (IN:[749..751] in)
        (NP
          (NP (DT:[752..753] a) (VBN:[755..768] reconstituted)
              (NN:[769..775] system))
          (VP (VBG:[776..786] containing)
            (NP (VBN:[787..795] purified) (NN:[796..800] fish)
               (NN:[801..805] P450) (NN:[806..815] reductase))
            (CC:[816..819] and)
            (NP (NN:[820..825] lipid))))))
    (.:[825..826] .)))

;sentence 7 Span:827..1007
;In  addition, effects of each individual components of the reconstituted
;system,  i.e., CYP1A1 and P450 reductase on 7-methoxyresorufin O-demethylase
;(MROD)  activity were studied.
;[915..921]:cyp450:"CYP1A1"
;[926..940]:substance:"P450 reductase"
;[944..976]:substance:"7-methoxyresorufin O-demethylase"
;[978..982]:substance:"MROD"
(SENT
  (S
    (PP (IN:[827..829] In)
      (NP (NN:[831..839] addition)))
    (,:[839..840] ,)
    (NP-SBJ-1
      (NP (NNS:[841..848] effects))
      (PP (IN:[849..851] of)
        (NP
          (NP
            (NP (DT:[852..856] each) (JJ:[857..867] individual)
                (NNS:[868..878] components))
            (PP (IN:[879..881] of)
              (NP (DT:[882..885] the) (VBN:[886..899] reconstituted)
                  (NN:[900..906] system))))
          (,:[906..907] ,)
          (NP
            (ADVP (FW:[909..913] i.e.))
            (,:[913..914] ,)
            (NP (NN:[915..921] CYP1A1))
            (CC:[922..925] and)
            (NP (NN:[926..930] P450) (NN:[931..940] reductase)))))
      (PP (IN:[941..943] on)
        (NP
          (NML
            (NML (NN:[944..962] 7-methoxyresorufin)
                 (NN:[963..976] O-demethylase))
            (NML (-LRB-:[977..978] -LRB-) (NN:[978..982] MROD)
                 (-RRB-:[982..983] -RRB-)))
          (NN:[985..993] activity))))
    (VP (VBD:[994..998] were)
      (VP (VBN:[999..1006] studied)
        (NP-1 (-NONE-:[1006..1006] *))))
    (.:[1006..1007] .)))

;sentence 8 Span:1008..1109
;7-ethoxyresorufin O-deethylase (EROD) activity was  strongly inhibited by
;alpha-naphthoflavone (ANF).
;[1008..1038]:substance:"7-ethoxyresorufin O-deethylase"
;[1040..1044]:substance:"EROD"
;[1082..1102]:substance:"alpha-naphthoflavone"
;[1104..1107]:substance:"ANF"
(SENT
  (S
    (NP-SBJ-1
      (NML
        (NML (NN:[1008..1025] 7-ethoxyresorufin) (NN:[1026..1038] O-deethylase))
        (NML (-LRB-:[1039..1040] -LRB-) (NN:[1040..1044] EROD)
             (-RRB-:[1044..1045] -RRB-)))
      (NN:[1046..1054] activity))
    (VP (VBD:[1055..1058] was)
      (ADVP-MNR (RB:[1060..1068] strongly))
      (VP (VBN:[1069..1078] inhibited)
        (NP-1 (-NONE-:[1078..1078] *))
        (PP (IN:[1079..1081] by)
          (NP-LGS
            (NP (NN:[1082..1102] alpha-naphthoflavone))
            (NP (-LRB-:[1103..1104] -LRB-) (NN:[1104..1107] ANF)
                (-RRB-:[1107..1108] -RRB-))))))
    (.:[1108..1109] .)))

;sentence 9 Span:1110..1132
;At 0.5 and 2.5 microM.
;[1113..1116]:quantitative-value:"0.5"
;[1121..1124]:quantitative-value:"2.5"
;[1125..1131]:quantitative-units:"microM"
(SENT
  (FRAG
    (PP (IN:[1110..1112] At)
      (NP
        (NP (CD:[1113..1116] 0.5)
          (NML-1 (-NONE-:[1116..1116] *P*)))
        (CC:[1117..1120] and)
        (NP (CD:[1121..1124] 2.5)
          (NML-1 (NN:[1125..1132] microM.)))))))

;sentence 10 Span:1133..1190
;ANF  inhibited EROD activity by 90 and 98%, respectively.
;[1133..1136]:substance:"ANF"
;[1148..1152]:substance:"EROD"
;[1165..1167]...[1174..1175]:quantitative-value:"90"..."%"
;[1172..1175]:quantitative-value:"98%"
(SENT
  (S
    (NP-SBJ (NN:[1133..1136] ANF))
    (VP (VBD:[1138..1147] inhibited)
      (NP (NN:[1148..1152] EROD) (NN:[1153..1161] activity))
      (PP-EXT (IN:[1162..1164] by)
        (NP
          (NP (CD:[1165..1167] 90)
            (NML-1 (-NONE-:[1167..1167] *P*)))
          (CC:[1168..1171] and)
          (NP (CD:[1172..1174] 98)
            (NML-1 (NN:[1174..1175] %)))))
      (,:[1175..1176] ,)
      (ADVP (RB:[1177..1189] respectively)))
    (.:[1189..1190] .)))

;sentence 11 Span:1191..1334
;Mullet CYP1A1 did not  catalyze monooxygenations of other substrates such as
;aniline, ethylmorphine,  N-nitrosodimethylamine and p-nitrophenol.
;[1198..1204]:cyp450:"CYP1A1"
;[1249..1259]:substance:"substrates"
;[1268..1275]:substance:"aniline"
;[1277..1290]:substance:"ethylmorphine"
;[1293..1315]:substance:"N-nitrosodimethylamine"
;[1320..1333]:substance:"p-nitrophenol"
(SENT
  (S
    (NP-SBJ (NN:[1191..1197] Mullet) (NN:[1198..1204] CYP1A1))
    (VP (VBD:[1205..1208] did) (RB:[1209..1212] not)
      (VP (VB:[1214..1222] catalyze)
        (NP
          (NP (NNS:[1223..1239] monooxygenations))
          (PP (IN:[1240..1242] of)
            (NP
              (NP (JJ:[1243..1248] other) (NNS:[1249..1259] substrates))
              (PP (JJ:[1260..1264] such) (IN:[1265..1267] as)
                (NP (NN:[1268..1275] aniline) (,:[1275..1276] ,)
                    (NN:[1277..1290] ethylmorphine) (,:[1290..1291] ,)
                    (NN:[1293..1315] N-nitrosodimethylamine)
                    (CC:[1316..1319] and) (NN:[1320..1333] p-nitrophenol))))))))
    (.:[1333..1334] .)))

;sentence 12 Span:1335..1478
;Antibodies produced against CYP1A1  orthologues in fish such as trout and
;scup showed strong cross-reactivity with  the purified mullet CYP1A1.
;[1335..1345]:substance:"Antibodies"
;[1363..1369]:cyp450:"CYP1A1"
;[1371..1382]:substance:"orthologues"
;[1471..1477]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1335..1345] Antibodies))
      (VP (VBN:[1346..1354] produced)
        (NP (-NONE-:[1354..1354] *))
        (PP (IN:[1355..1362] against)
          (NP (NN:[1363..1369] CYP1A1) (NNS:[1371..1382] orthologues)))
        (PP-LOC (IN:[1383..1385] in)
          (NP
            (NP (NNS:[1386..1390] fish))
            (PP (JJ:[1391..1395] such) (IN:[1396..1398] as)
              (NP (NN:[1399..1404] trout) (CC:[1405..1408] and)
                  (NN:[1409..1413] scup)))))))
    (VP (VBD:[1414..1420] showed)
      (NP
        (NP (JJ:[1421..1427] strong) (AFX:[1428..1433] cross)
            (HYPH:[1433..1434] -) (NN:[1434..1444] reactivity))
        (PP (IN:[1445..1449] with)
          (NP (DT:[1451..1454] the) (VBN:[1455..1463] purified)
              (NN:[1464..1470] mullet) (NN:[1471..1477] CYP1A1)))))
    (.:[1477..1478] .)))

;sentence 13 Span:1479..1692
;In addition, anti-L. saliens liver CYP1A1 produced  in our laboratory
;inhibited both the EROD and MROD activities catalyzed by L.  saliens liver
;microsomes but stronger inhibition was observed with EROD  activity.
;[1492..1520]:cyp450:"anti-L. saliens liver CYP1A1"
;[1568..1572]:substance:"EROD"
;[1577..1581]:substance:"MROD"
;[1677..1681]:substance:"EROD"
(SENT
  (S
    (S
      (PP (IN:[1479..1481] In)
        (NP (NN:[1482..1490] addition)))
      (,:[1490..1491] ,)
      (NP-SBJ
        (NP
          (NML (AFX:[1492..1496] anti) (HYPH:[1496..1497] -)
            (NML (NNP:[1497..1499] L.) (NNP:[1500..1507] saliens)))
          (NN:[1508..1513] liver) (NN:[1514..1520] CYP1A1))
        (VP (VBN:[1521..1529] produced)
          (NP (-NONE-:[1529..1529] *))
          (PP-LOC (IN:[1531..1533] in)
            (NP (PRP$:[1534..1537] our) (NN:[1538..1548] laboratory)))))
      (VP (VBD:[1549..1558] inhibited)
        (NP
          (NP (CC:[1559..1563] both)
            (NP (DT:[1564..1567] the) (NN:[1568..1572] EROD)
              (NML-2 (-NONE-:[1572..1572] *P*)))
            (CC:[1573..1576] and)
            (NP (NN:[1577..1581] MROD)
              (NML-2 (NNS:[1582..1592] activities))))
          (VP (VBN:[1593..1602] catalyzed)
            (NP (-NONE-:[1602..1602] *))
            (PP (IN:[1603..1605] by)
              (NP-LGS
                (NML (NNP:[1606..1608] L.) (NNP:[1610..1617] saliens))
                (NN:[1618..1623] liver) (NNS:[1624..1634] microsomes)))))))
    (CC:[1635..1638] but)
    (S
      (NP-SBJ-1 (JJR:[1639..1647] stronger) (NN:[1648..1658] inhibition))
      (VP (VBD:[1659..1662] was)
        (VP (VBN:[1663..1671] observed)
          (NP-1 (-NONE-:[1671..1671] *))
          (PP (IN:[1672..1676] with)
            (NP (NN:[1677..1681] EROD) (NN:[1683..1691] activity))))))
    (.:[1691..1692] .)))

;sentence 14 Span:1693..1863
;On the other hand, anti-mullet CYP1A1 antibodies showed very weak 
;cross-reactivity with two proteins (presumably CYP1A1 and CYP1A2) in
;3MC-treated  rat liver microsomes.
;[1712..1741]:substance:"anti-mullet CYP1A1 antibodies"
;[1786..1794]:cyp450:"proteins"
;[1807..1813]:cyp450:"CYP1A1"
;[1818..1824]:cyp450:"CYP1A2"
;[1829..1832]:substance:"3MC"
(SENT
  (S
    (PP (IN:[1693..1695] On)
      (NP (DT:[1696..1699] the) (JJ:[1700..1705] other) (NN:[1706..1710] hand)))
    (,:[1710..1711] ,)
    (NP-SBJ
      (NML (AFX:[1712..1716] anti) (HYPH:[1716..1717] -)
           (NN:[1717..1723] mullet))
      (NN:[1724..1730] CYP1A1) (NNS:[1731..1741] antibodies))
    (VP (VBD:[1742..1748] showed)
      (NP
        (NP
          (ADJP (RB:[1749..1753] very) (JJ:[1754..1758] weak))
          (AFX:[1760..1765] cross) (HYPH:[1765..1766] -)
           (NN:[1766..1776] reactivity))
        (PP (IN:[1777..1781] with)
          (NP
            (NP (CD:[1782..1785] two) (NNS:[1786..1794] proteins))
            (PRN (-LRB-:[1795..1796] -LRB-)
              (FRAG
                (ADVP (RB:[1796..1806] presumably))
                (NP (NN:[1807..1813] CYP1A1) (CC:[1814..1817] and)
                    (NN:[1818..1824] CYP1A2)))
              (-RRB-:[1824..1825] -RRB-)))))
      (PP-LOC (IN:[1826..1828] in)
        (NP
          (ADJP (NN:[1829..1832] 3MC) (HYPH:[1832..1833] -)
                (VBN:[1833..1840] treated))
          (NN:[1842..1845] rat) (NN:[1846..1851] liver)
           (NNS:[1852..1862] microsomes))))
    (.:[1862..1863] .)))

;sentence 15 Span:1864..1979
;Moreover, 3MC-treated rat liver microsomal EROD activity  was weakly
;inhibited by the anti-L. saliens liver CYP1A1.
;[1874..1877]:substance:"3MC"
;[1907..1911]:substance:"EROD"
;[1950..1978]:cyp450:"anti-L. saliens liver CYP1A1"
(SENT
  (S
    (ADVP (RB:[1864..1872] Moreover))
    (,:[1872..1873] ,)
    (NP-SBJ-1
      (NML
        (ADJP (NN:[1874..1877] 3MC) (HYPH:[1877..1878] -)
              (VBN:[1878..1885] treated))
        (NN:[1886..1889] rat) (NN:[1890..1895] liver)
         (JJ:[1896..1906] microsomal) (NN:[1907..1911] EROD))
      (NN:[1912..1920] activity))
    (VP (VBD:[1922..1925] was)
      (ADVP (RB:[1926..1932] weakly))
      (VP (VBN:[1933..1942] inhibited)
        (NP-1 (-NONE-:[1942..1942] *))
        (PP (IN:[1943..1945] by)
          (NP-LGS (DT:[1946..1949] the)
            
            (NML (AFX:[1950..1954] anti) (HYPH:[1954..1955] -)
              (NML (NNP:[1955..1957] L.) (NNP:[1958..1965] saliens)))
            (NN:[1966..1971] liver) (NN:[1972..1978] CYP1A1)))))
    (.:[1978..1979] .)))

;sentence 16 Span:1980..2237
;These results strongly  suggested that the purified mullet CYP1A1 is
;structurally, functionally and  immunochemically similar to the CYP1A1
;homologues purified from other teleost  species but functionally and
;immunochemically distinct from mammalian CYP1A1.
;[2039..2045]:cyp450:"CYP1A1"
;[2113..2119]:cyp450:"CYP1A1"
;[2120..2130]:substance:"homologues"
;[2230..2236]:cyp450:"CYP1A1"
(SENT
  (S
    (NP-SBJ (DT:[1980..1985] These) (NNS:[1986..1993] results))
    (ADVP (RB:[1994..2002] strongly))
    (VP (VBD:[2004..2013] suggested)
      (SBAR (IN:[2014..2018] that)
        (S
          (NP-SBJ (DT:[2019..2022] the) (VBN:[2023..2031] purified)
                  (NN:[2032..2038] mullet) (NN:[2039..2045] CYP1A1))
          (VP (VBZ:[2046..2048] is)
            (ADJP-PRD
              (ADJP
                (ADVP (RB:[2049..2061] structurally) (,:[2061..2062] ,)
                      (RB:[2063..2075] functionally) (CC:[2076..2079] and)
                      (RB:[2081..2097] immunochemically))
                (JJ:[2098..2105] similar)
                (PP (TO:[2106..2108] to)
                  (NP
                    (NP (DT:[2109..2112] the) (NN:[2113..2119] CYP1A1)
                        (NNS:[2120..2130] homologues))
                    (VP (VBN:[2131..2139] purified)
                      (NP (-NONE-:[2139..2139] *))
                      (PP (IN:[2140..2144] from)
                        (NP (JJ:[2145..2150] other) (NN:[2151..2158] teleost)
                            (NNS:[2160..2167] species)))))))
              (CC:[2168..2171] but)
              (ADJP
                (ADVP (RB:[2172..2184] functionally) (CC:[2185..2188] and)
                      (RB:[2189..2205] immunochemically))
                (JJ:[2206..2214] distinct)
                (PP (IN:[2215..2219] from)
                  (NP (JJ:[2220..2229] mammalian) (NN:[2230..2236] CYP1A1)))))))))
    (.:[2236..2237] .)))

;section 17 Span:2241..2286
;PMID: 11048673 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2241..2245] PMID) (::[2245..2246] :) (CD:[2247..2255] 11048673)
        (NN:[2256..2257] -LSB-) (NNP:[2257..2263] PubMed) (::[2264..2265] -)
        (NN:[2266..2273] indexed) (IN:[2274..2277] for)
        (NNP:[2278..2286] MEDLINE-RSB-)))
